101 related articles for article (PubMed ID: 262769)
1. LATS-protector activity in thyrotoxicosis measured by thyroidal intracellular colloid droplet formation.
Shishiba Y; Miyachi Y; Takaishi M; Ozawa Y
J Clin Endocrinol Metab; 1978 May; 46(5):841-8. PubMed ID: 262769
[TBL] [Abstract][Full Text] [Related]
2. Correlation between long-acting thyroid stimulator protector level and thyroid 131-I uptake in thyrotoxicosis.
Adams DD; Kennedy TH; Stewart RD
Br Med J; 1974 Apr; 2(5912):199-201. PubMed ID: 4406686
[TBL] [Abstract][Full Text] [Related]
3. Long-acting thyroid stimulator (LATS) and long acting thyroid stimulator protector (LATS-P) in untreated thyrotoxicosis.
Hardisty CA; Hanford L; Humphries H; Munro DS
Clin Endocrinol (Oxf); 1981 Jun; 14(6):631-9. PubMed ID: 6895353
[TBL] [Abstract][Full Text] [Related]
4. Evidence that both long-acting thyroid stimulator and long-acting thyroid stimulator-protector stimulate the human thyroid gland.
Holmes SD; Dirmikis SM; Martin TJ; Munro DS
J Endocrinol; 1979 Feb; 80(2):215-21. PubMed ID: 220366
[TBL] [Abstract][Full Text] [Related]
5. Absence of allotypic variation in the autoantigen for thyroid stimulating autoantibodies.
Knight A; Adams DD
Clin Exp Immunol; 1983 May; 52(2):317-24. PubMed ID: 6134598
[TBL] [Abstract][Full Text] [Related]
6. Transient thyrotoxicosis in an infant delivered to a long-acting thyroid stimulator (LATS)- and LATS protector-negative, thyroid-stimulating antibody-positive woman with Hashimoto's thyroiditis.
Hoffman WH; Sahasrananan P; Ferandos SS; Burek CL; Rose NR
J Clin Endocrinol Metab; 1982 Feb; 54(2):354-6. PubMed ID: 6119322
[TBL] [Abstract][Full Text] [Related]
7. Dissociation of serum LATS activity and hyperfunction and autonomy of the thyroid gland in Graves' disease.
Hennemann G; Dolman A; Docter R; De Reus A; Van Zijl J
J Clin Endocrinol Metab; 1975 Jun; 40(6):935-41. PubMed ID: 1173367
[TBL] [Abstract][Full Text] [Related]
8. Thyroid carcinoma and concurrent hyperthyroidism: a study of ten patients.
Hancock BW; Bing RF; Dirmikis SM; Munro DS; Neal FE
Cancer; 1977 Jan; 39(1):298-302. PubMed ID: 832245
[TBL] [Abstract][Full Text] [Related]
9. Dissociation of serum LATS content and thyroid suppressibility during treatment of hyperthyroidism.
Chopra IJ; Solomon DH; Johnson DE; Chopra U; Fischer DA
J Clin Endocrinol Metab; 1970 Apr; 30(4):524-8. PubMed ID: 5435290
[No Abstract] [Full Text] [Related]
10. [Evolution of immunoglobulins IgA, IgM, IgG and LATS during treatment of hyperthyroidism with carmibazole and radioiodine].
Mahaux JE; Delcourt R; Nagel M; Chamla-Soumenkoff J; Levin S
Ann Endocrinol (Paris); 1970; 31(2):314-23. PubMed ID: 4192759
[No Abstract] [Full Text] [Related]
11. Characterization of monoclonal antibodies raised against solubilized thyrotropin receptors in a cytochemical bioassay for thyroid stimulators.
Ealey PA; Valente WA; Ekins RP; Kohn LD; Marshall NJ
Endocrinology; 1985 Jan; 116(1):124-31. PubMed ID: 2856871
[TBL] [Abstract][Full Text] [Related]
12. Effects of long-acting thyroid stimulator (LATS) and LATS protector on human thyroid adenyl cyclase activity.
Kendall-Taylor P
Br Med J; 1973 Jul; 3(5871):72-5. PubMed ID: 4740444
[TBL] [Abstract][Full Text] [Related]
13. Direct evidence for human thyroidal stimulation by LATS-protector.
Shishiba Y; Shimizu T; Yoshimura S; Shizume K
J Clin Endocrinol Metab; 1973 Mar; 36(3):517-21. PubMed ID: 4739312
[No Abstract] [Full Text] [Related]
14. Specific and nonspecific responses in the bioassay of long-acting thyroid stimulator (LATS).
Chopra IJ; Solomon DH; Limberg NP
J Clin Endocrinol Metab; 1970 Oct; 31(4):382-90. PubMed ID: 5468701
[No Abstract] [Full Text] [Related]
15. Effects of in vivo triiodothyronine and long acting thyroid stimulator (LATS) administration on the vitro thyroid cAMP response to thyrotrophin and LATS.
Ikeda H; Chiu SC; Kuzuya N; Uchimura H; Nagataki S
Acta Endocrinol (Copenh); 1984 Jun; 106(2):193-8. PubMed ID: 6328822
[TBL] [Abstract][Full Text] [Related]
16. Discrepancy between thyroid-stimulating and thyrotropin-binding inhibitory activities of Graves' immunoglobulin Gs assessed in the mouse.
Shishiba Y; Ozawa Y; Ohtsuki N; Shimizu T
J Clin Endocrinol Metab; 1982 Apr; 54(4):858-62. PubMed ID: 6277983
[TBL] [Abstract][Full Text] [Related]
17. Lack of refractoriness to stimulation with long acting thyroid stimulator of thyroid hormone synthesis and thyroid hormone secretion in mice in vivo.
Ikeda H; Nagataki S
Acta Endocrinol (Copenh); 1983 Mar; 102(3):392-5. PubMed ID: 6829264
[TBL] [Abstract][Full Text] [Related]
18. Sensitivity and specificity of blood and thyroid radio-iodine assays for TSH and LATS and inhibitory effect of corticosteroid.
Sharard A
N Z Med J; 1975 Jan; 81(531):21-2. PubMed ID: 1055309
[No Abstract] [Full Text] [Related]
19. Detection and properties of TSH-binding inhibitor immunoglobulins in patients with Graves' disease and Hashimoto's thyroiditis.
Endo K; Kasagi K; Konishi J; Ikekubo K; Okuno T; Takeda Y; Mori T; Torizuka K
J Clin Endocrinol Metab; 1978 May; 46(5):734-9. PubMed ID: 45421
[TBL] [Abstract][Full Text] [Related]
20. Stimulation of the human thyroid by infusions of plasma containing LATS protector.
Adams DD; Fastier FN; Howie JB; Kennedy TH; Kilpatrick JA; Stewart RD
J Clin Endocrinol Metab; 1974 Nov; 39(5):826-32. PubMed ID: 4425101
[No Abstract] [Full Text] [Related]
[Next] [New Search]
